Given these observations, the authors exploited these experimental models to successfully test the efficacy of a novel therapeutic strategy, combining anti-MICA/B antibodies (thus increasing the immune-mediated cytotoxic effects) and an anti-NKG2A antibody (thus avoiding tumor immune-escape), showing a relevant synergistic action [122]. This evidence concerns the gene KLRC1 and neoplasm.